KZIA · Kazia Therapeutics Ltd
Market Cap
$155.18M
Shares
11.43M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.58
Open$15.48
Day$13.30–15.50
52W close$5.00–16.90
Avg vol 30d247K
Short int559K · 4.9% float · 2.7d
Short vol48%
DataApr 2025–Aug 2026
Raw chart and full-history price indicators begin at the captured split on Apr 17, 2025; bars on opposite sides are not compared.
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+31%
above
Price vs 50-day avg
+1%
above
RSI (14)
50
neutral
MACD trend
Positive
52-week position
72%
mid-range
Momentum
relative strength
1-month return
+8%
trailing
6-month return
+65%
trailing
YTD return
+97%
this year
Relative strength
+52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
+57% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.89% of float · ▼ -17.7% MoM · 2.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
36 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
125%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
9.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+31%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
72%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $13 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
+57% holders QoQ · +18 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.89% of float · ▼ -17.7% MoM · 2.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
36 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $14 · 72%
Range high $17
vs 200-day avg +31%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KZIA
this stock
Kazia Therapeutics Ltd
|
$155.18M | +97.1% | — | — | 4.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Performance
Raw-price comparisons begin at the captured split on Apr 17, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KZIA | +1.3% | +7.6% | +65.2% | +7.6% | +97.1% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +0.8% | +4.6% | +51.8% | +4.6% | +84.3% |
Key facts
CIK
1075880
CUSIP
48669G303
13F (30d)
35 filings
34 filers
Visit website
Investor relations